SLN124 (Silence Therapeutics)

	Next higher product group	RNAi drug (RNAi therapeutic)
	Status	2018-07-17 development pp existent
	Organisation	Silence Therapeutics plc (Nasdaq: SLN)
	Group	Silence Therapeutics (Group)

Silence Therapeutics plc. (8/5/19). "Press Release: Silence Therapeutics Appoints Jørgen Wittendorff as Head of Manufacturing". London.

Silence Therapeutics, PLC (LON: SLN) (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, is pleased to announce that Jørgen Wittendorff has been appointed to the new role of Head of Manufacturing at Silence Therapeutics. Joining the Company’s senior management team, he will be responsible for the process development and manufacturing of siRNA therapeutic products for clinical trials and, ultimately, commercial use.

Mr. Wittendorff brings with him over 25 years of experience in the development of pharmaceutical products, having previously held various senior positions within the industry. Most recently, he was Senior Director, CMC Manufacturing and Product Supply at Ablynx, later acquired by Sanofi for EUR 3.9 billion, where he oversaw complex CMC manufacturing processes and regulatory filing of biologics, amongst other key functions. Mr Wittendorff’s successful track record is further proven by senior positions at Ferring Pharmaceuticals and Novo Nordisk.

Mr. Wittendorff obtained a master’s degree in Pharmacy from the University of Copenhagen. Dr. David Horn Solomon, Chief Executive Officer of Silence Therapeutics, commented: “Jørgen’s extensive experience in complex manufacturing from Ablynx will be a significant contribution to Silence and it is a pleasure to welcome someone of his calibre to the senior management team. In his new role, Jørgen will be able to critically contribute to the manufacturing efforts to progress Silence’s three significant sets of assets in gene silencing siRNA: SLN124, for the treatment of iron overload disorders, SL360, for the treatment of cardiovascular disease, and SL500 with partner Mallinckrodt Pharmaceuticals, for the treatment of complement-mediated disorders.”

Jørgen Wittendorff, newly appointed Head of Manufacturing of Silence Therapeutics, commented: “Silence has an impressive portfolio of assets in the siRNA field and it is exciting to be involved in the development of products which have the potential to positively impact the lives of patients with serious diseases. I look forward to working with the rest of the senior management team at this exciting point in the company’s journey.”

Enquiries:

Silence Therapeutics plc Dr David Horn Solomon, Chief Executive Officer Iain Ross, Chairman
Tel: +44 (0)20 3457 6900

Peel Hunt LLP (Nominated Adviser and Broker) James Steel/Oliver Jackson
Tel: +44 (0)20 7418 8900

European IR Consilium Strategic Communications Mary-Jane Elliott/Chris Welsh/Angela Gray silencetherapeutics@consilium-comms.com
Tel: +44 (0) 20 3709 5700

US IR Westwicke Partners Peter Vozzo peter.vozzo@westwicke.com
Tel: +1 (443) 213-0505

About Silence Therapeutics plc

Silence Therapeutics is developing a new generation of medicines by harnessing the body’s natural mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using its enabling delivery systems, it has achieved an additional level of specificity by delivering its therapeutic RNA molecules exclusively to target cells. Silence’s proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases. For more information, please visit: https://www.silence-therapeutics.com/